Overview

Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)

Status:
Active, not recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with previously untreated metastatic pancreatic cancer.

Phase:

Phase 2

Details

Lead Sponsor:

HonorHealth Research Institute

Collaborators:

Abramson Cancer Center of the University of Pennsylvania
Barts Cancer Institute
Cancer Research UK
Cancer Research UK (CRUK)
Imaging Endpoints
Lustgarten Foundation
Mayo Clinic
Princeton University
Salk Institute for Biological Studies
Stand Up To Cancer
Translational Genomics Research Institute
University of California, San Diego

Treatments:

Albumin-Bound Paclitaxel
Cisplatin
Ergocalciferols
Gemcitabine
Paclitaxel